abstract |
A fusion protein comprising an interleukin-1 receptor antagonist (IL-1ra) with all or part of a constant domain of a heavy or light chain of human immunoglobulin at the carboxy-terminus is disclosed. The fusion protein exhibits a therapeutic effect on inflammation and is useful for treating IL-1 mediated inflammatory diseases, particularly diseases of the joint. |